Indivior Pharmaceuticals annual operating margin
2021
2022
2023
2024
2025
Indivior Pharmaceuticals Operating Margin Growth & History (INDV)
Indivior Pharmaceuticals's operating margin was 21.15% for fiscal 2025.
View full Indivior Pharmaceuticals company overviewIndivior Pharmaceuticals annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 21.15% | +17.95 pp |
| 2024 | 2024-12-31 | 3.20% | +17.11 pp |
| 2023 | 2023-12-31 | −13.91% | −4.92 pp |
| 2022 | 2022-12-31 | −8.99% | −35.92 pp |
| 2021 | 2021-12-31 | 26.93% | — |
Indivior Pharmaceuticals quarterly operating margin
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 46.65% | +22.81 pp |
| Q1 2026 | 2026-03-31 | 43.22% | +18.41 pp |
| Q4 2025 | 2025-12-31 | 22.69% | +7.25 pp |
| Q3 2025 | 2025-09-30 | 13.69% | +2.29 pp |
| Q2 2025 | 2025-06-30 | 23.84% | +63.31 pp |
| Q1 2025 | 2025-03-31 | 24.81% | −1.60 pp |
| Q4 2024 | 2024-12-31 | 15.44% | — |
| Q3 2024 | 2024-09-30 | 11.40% | — |
| Q2 2024 | 2024-06-30 | −39.46% | — |
| Q1 2024 | 2024-03-31 | 26.41% | — |
Indivior Pharmaceuticals operating margin trends
Across the available reported history, Indivior Pharmaceuticals's operating margin increased from 3.20% to 21.15%, a change of +17.95 percentage points. The latest reported quarter, Q2 2026, shows 46.65%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Indivior Pharmaceuticals filings at SEC.gov ↗